SlideShare a Scribd company logo
MODERATOR – Prof. DR. - ANIL KAPOORMODERATOR – Prof. DR. - ANIL KAPOOR
What Is Myelodysplastic Syndrome?
The myelodysplastic syndromes are a group of disorders
characterized by one or more peripheral blood cytopenias
secondary to bone marrow dysfunction.
 In MDS the bone marrow cannot produce blood cells
effectively, and many of the blood cells formed are
defective.
These abnormal blood cells are usually destroyed before
they leave the bone marrow or shortly after entering the
bloodstream.
As a result, patients have shortages of blood cells, which
are reflected in their low blood
Characteristics
Varying degree of tri-lineage cytopenia ( red blood
cells, white blood cells and platelets).
Dysplasia
Normocellular or hypercellular B.M.
May progress to acute leukaemia
Incidence
1- Disease of elderly.
2- Median age is 65 years.
3- <10% are younger than 50 years.
4- Incidence rates 1/100,000 pop./ years.
5- Incidence rise to 1/1000 / years in > 60 years old.
6- Male slightly higher than female
MDS Etiology
Two etiologic categories of MDS:
1.) De Novo:
Associated with:
-benzene exposure (gasoline)
-cigarette smoking
-viruses -Fanconi’s anemia
2.) Therapy related:
Associated with:
-alkylating agent chemotherapy
-radiation
Aetiological Agents
 Tobacco smoke.
 Ionizing radiation.
 Organic chemicals (such as benzene, toluene, xylene, and
chloramphenicol).
 Heavy metals.
 Herbicides.
 Pesticides.
 Fertilizers.
 Stone and cereal dusts.
 Exhaust gases.
 Nitro-organic explosives.
 Petroleum and diesel derivatives.
 Alkylating agents.
 Marrow-damaging agents used in cancer chemotherapy.
Pathophysiology: Contributing Factors
MDS
Stem cell
dysfunction
Stem Cell
Dysfunction
ApoptosisApoptosis
Stromal/
angiogenic
factors
Stromal/
angiogenic
factors
Epigenetic
changes
Epigenetic
changes
Immune
dysfunction
Immune
dysfunction
Environmental
direct toxicity
Environmental
direct toxicity
Mutations/
DNA damage
Mutations/
DNA damage
With Permission of J. Maciejewski, M.D.
Taussig Cancer Center/ Cleveland Clinic Foundation
Myelodysplastic Syndrome
Dyserythropoiesis
Dysmyelopoiesis
Dysmegakaryopoiesis
Ring Sideroblast
Type I and II blasts
Dyserythropoiesis
Anemia
Normocytic or macro-ovalocytes
Low retic count
NRBC
Megaloblastic changes
Ringed sideroblast
Pappenheimer bodies
Basophilic stippling
Dyserythropoiesis
Ringed sideroblast
Dysmyelopoiesis
Neutropenia
Monocytosis
Pseudo Pelger-Huet
Hypogranular PMN
<20% blasts in BM
Type I and type II blasts
Blasts in MDS
Type I blasts
No granules
Prominent
nucleoli
Central nucleus
Type II and III blasts
Few 1o
granules
Prominent
nucleoli
Central nucleus
Promyelocyte
Many 1o
granules
Less prominent
nucleoli
Eccentric nucleus
Type I Blast
Type III Blast
Dysmegakaryopoiesis
Low platelet count
Giant Platelet
Dwarf (micro) megakaryocyte
Abnormal platelets
Micromegakaryocyte
Chromosomal abnormalities and MDS
Chromosomal abnormalities are present in up to
50%of de novo cases of MDS and in virtually all
cases of secondary MDS. The most common are:
 Abnormality - 7 +7 +8 5q- 7q- 11q- 12q- 13q- 20q- inv3 i(17q) t(1;3) t(1;7) t(3;3)
 Frequency(%) 15 5 19 27 4 7 5 2 5 1 5 1 2 1
Deletion of the long arm of chromosome 5
(5q- syndrome )
Strongly associated with RA.
5q- accounts for up to 70% of cytogenetic abnormalities in
this subtype.
The q arm of chromosome 5 is particularly rich in genes,
which encoded haemopoietic growth factors and their
receptors. For example , IL-3 , IL-4 , IL-5 , GM-CSF and the
M-CSF receptor are located in this region.
The potential for the loss of any or all of these genes
contribute to the disruption of ordered haemopoiesis.
Monosmy 7 and 7q-
Most strongly associated with secondary MDS.
Associated with the loss of a major surface
glycoprotein (gp 130) in neutrophile and susceptibility
to bacterial infection secondary to impaired
granulocyte monocyte chemotatic activity.
Deletion of the q arm of chromosome 11
(11q-)
Account for 20% of the chromosomal abnormalities
in RAS.
This abnormality is associated with raised iron stores
and high ring sidroblast counts.
 The presence of the gene , which encoded the H-
subunit of ferritin at chromosome 11 , may explain
this
Abnormalities of chromosome 17 (i17q)
It involves the loss or disruption of the Р53 tumor
suppressor gene are seen in CML in association with
transformation to the blastic phase and in up to 5%
of cases of primary MDS.
 This predisposes to certain dysplastic features and
neutrophil vaculation.
Abnormalities of chromosome 3
Dysmegakaryopiesis and thombocytosis appear to be
associated with Abnormalities of chromosome 3
The importance of indication of chromosomal
abnormalities
To confirm diagnoses .
 To know the stage of disease.
To know the direction of progression of disease.
Multiple genetic abnormalities indicate late events in
MDS.
Abnormal localization of immature
precursors
Presence of 3 or more small clusters of myeloblasts
and promyelocytes (5 – 8 cells) in marrow trephine
biopsy in the central portion of the marrow away
from the vascular structure and the endosteal
surface of the bone trabeculae
Abnormal localization of immature
precursors
Signs and Symptoms
Excessive tiredness, shortness of breath, and pale skin can
be caused by anemia (shortage of red blood cells).
Serious infections with high fevers can be caused by
leukopenia (not having enough normal white blood cells)
and, in particular, by having neutropenia or
granulocytopenia (too few mature granulocytes).
Excessive bruising and bleeding, for example, frequent or
severe nosebleeds and/or bleeding from the gums, can be
due to thrombocytopenia (not having enough of the blood
platelets needed for plugging holes in damaged blood
vessels).
Physical Exam
Hepatomegaly, splenomegaly, LAD:
uncommon
Except CMML
Cutaneous manifestations: uncommon
Sweet’s syndrome( neutrophilic dermatosis):
transformation to acute leukemia ( IL-6)
Granulocytic sarcoma (chloroma): herald disease
transformation into acute leukemia
Sweet’s syndrome

FAB classification scheme in 1985 for MDS
Refractory Anemia
RA Definition:
Dyplasia of the erythroid series only.
Clinically, anemia is refractory to hematinic
therapy
Myeloblasts < 1% blood and < 5% marrow
<15% ringed sideroblasts in marrow
No Auer rods
Other etiologies of erythroid abnormalities must
be excluded. These include:
drug/toxin exposure -vitamin deficiency
viral infection -congenital disease
Refractory Anemia
Epidemiology:
5-10% of MDS cases.
Older patients
Morphology:
Anisopoikilocytosis on peripheral smears
Dyserythropoiesis with nuclear abnormalities
(megaloblastoid change)
< 15% ringed sideroblasts
Refractory Anemia
Genetics:
25% may have genetic abnormalities
Prognosis:
Median survival is 66 months
6% rate of progression to acute leukemia
Peripheral Smear - Anisopoikilocytosis
Megaloblastoid Change on Bone Marrow
Aspirate
Refractory Anemia with Ringed Sideroblasts
RARS definition:
Dyplasia of the erythroid series only.
Clinically, anemia is refractory to hematinic
therapy
Myeloblasts < 5% in marrow, absent in blood
>15% ringed sideroblasts in marrow
No Auer rods
Other etiologies of ringed sideroblasts must be
excluded. These include:
Anti- tuberculosis drugs
Alcoholism
Refractory Anemia with Ringed Sideroblasts
Epidemiology:
10-12% of MDS cases.
Older patients
Males > females
Morphology:
Dimorphic pattern on peripheral smears
Majority RBC’s normochromic, 2nd
population
hypochromic
Dyserythropoiesis with nuclear abnormalities
(megaloblastoid change)
Refractory Anemia with Ringed Sideroblasts
Genetics:
Clonal chromosomal abnormalities in
 <10%; in fact, development of such an
abnormality should prompt reassessment of
diagnosis.
Prognosis:
Median survival 6 years (72 months)
1-2% rate of progression to acute leukemia
Dimorphic Red Cell Population
Ringed Sideroblasts
Ringed Sideroblasts
Megaloblastoid Change
Refractory Anemia with Excess Blasts
RAEB definition:
Refractory anemia with 5-19% myeloblasts in the
bone marrow.
RAEB-1:
 5-9% blasts in bone marrow and <5% blasts in blood.
RAEB-2:
 10-19% blasts in the bone marrow
 Auer rods present
Refractory Anemia with Excess Blasts
Epidemiology: 40% of MDS cases.
Older patients (over 50 years)
Morphology:
Dysplasia of all three cell lines often present
Neutrophil abnormalities may include:
Hypogranulation
Pseudo-Pelger-huet (hyposegmentation/barbells)
Megkaryocyte abnormalities may include
Hypolobation -Micromegakaryocytes
Refractory Anemia with Excess Blasts
Morphology (con’t.)
Erythroid precursor abnormalities may include:
Abnormal lobulation -megaloblastoid change
Multinucleation
0-19% myeloblasts in the blood
5-19% in the marrow
Bone marrow:
Usually hypercellular (10-15% hypocellular)
Abnormal localization of immature precursors (ALIP) may be
present
Immunophenotype:
Blasts express CD 13, CD33 or CD117
Refractory Anemia with Excess Blasts
Genetics:
Clonal chromosomal abnormalities found in 30% - 50% of
RAEB cases. The abnormalities include:
+8 – -5 – del(5q)
– -7 – del(7q) – Complex karyotypes
Prognosis:
Median survival, RAEB-1 = 18 months
Median survival, RAEB-2 = 10 months
RAEB-1 = 25% rate of progression to acute leukemia
RAEB-2 = 33% rate of progression to acute leukemia
Hypercellular Bone Marrow
Auer Rods
Refractory Anemia with Excess Blasts in
Transformation (RAEB-t)
•
21-30 percent blasts in the marrow; more than
5 percent in the bloodstream
•
normal or hypercellular (filled with cells)
marrow
•
accounts for about 25 percent of cases
Chronic Myelomonocytic Leukemia
(CMML)
•
5-20 percent blasts in the marrow; less than 5
percent in the bloodstream
•
cytopenia of at least two cell lines
•
normal or hypercellular (filled with cells)
marrow
•
accounts for 15 to 20 percent of cases.
CMML
 Splenomegaly (10%)
 Maculopapular skin infiltration
 Monocytic pleural or pericardial effusion
 JMML (MPD/MDS)
1. Pallor, bleeding, hepatosplenomegaly, skin
involvement
WHO
Refractory anemia
Refractory anemia e ringed siderblast
Refractory cytopenia e multilineage dysplasia
Refractory cytopenia e multilineage dysplasia &
ringed sideroblasts
Refractory anemia e excess blast-1
Refractory anemia e excess blast-2
Myelodysplastic syndrome unclassified
MDS associated e isolated del (5q)
WHO
Subtype Blood Bone Marrow
RA Anemia Erythroid
dysplasia only
RARS Anemia Erythroid dys
>15% ringed
RCMD Bi- pancytopenia >10%Dysp in 2
or more cell
lineage
RCMD-RS Bi-pancytopenia >10%Dys 2 or
more cell lineage
>15% ringed
WHO
subtype Blood Bone Marrow
RAEB-1 Cytopenia
<5% blast
Uni-multilineage
dys, 5-9%blast
RAEB-2 Cytopenia,
5-19%blast or Auer
rods
Uni-multi dys
10-19%blast
Or Auer rods
MDS-U cytopenia Myeloid or
megakaryocte dys
MDS with 5q Anemia,nor or
increased PLT
Mega e hypolobated
nuclei, <5%blast
Prognostic Groups
Two groups based on survival and evolution to acute
leukemia
1.) “Good” group
Refractory anemia (RA)
Refractory anemia with ringed sideroblasts (RARS)
5q - syndrome
2.) “Bad” group
Refractory anemia with excess blasts (RAEB)
Refractory anemia with excess blasts in transformation (RAEB-t)
CMML
MDS unclassified can be either
International Prognostic Scoring System
(IPSS) Factors
(1) the percentage of blasts in the bone
marrow.
(2)whether chromosome abnormalities are
present and, if so, which ones.
(3)how low the patient's blood counts are. These
are given a score; the lowest scores have the
best outlook for survival.
Prognostic Scoring
The International Myelodysplastic Syndrome Working
Group developed a scoring system based on 3 variables:
00 0.50.5 1.01.0 1.51.5 2.02.0
% Blasts% Blasts
<5<5 5-105-10 ---- 11-2011-20 20-3020-30
KaryotypKaryotyp
ee
Normal, -Y,Normal, -Y,
del(5q),del(5q),
del(20q)del(20q)
SingleSingle
karyotypickaryotypic
anomaly,anomaly,
DoubleDouble
abnormaliyabnormaliy
≥≥ 33
abnormalities,abnormalities,
chr 7chr 7
abnormalitiesabnormalities
Chr 3 abn.Chr 3 abn.
CytopeniCytopeni
aa
0-10-1 2-32-3
Median Survival in MDS
MDS: Differential Diagnosis
B12/folate deficiency
Heavy metals (Arsenic)
Congenital dyserythropoietic anemia
Parvovirus B19
GCSF therapy (increased blasts)
Treatment
o Chemotherapy.
o Supportive therapy, such as WBCs, RBCs,
Platelets transfusions.
o B.M transplantation in young patients.
THANK YOU
SPEAKER- DR. Narmada Prasad TiwariSPEAKER- DR. Narmada Prasad Tiwari
Prevention & Treatment
of Infections
Prevention
Prophylactic antibiotics  no role
Patient education  know your nadir
report a fever
recognize signs of infection
avoid illness, crowds
update vaccinations
Treatment  Febrile neutropenia guidelines
www.nccn.org/MDS v1..2008
Iron Chelation Options
Deferoxamine (Desferal®)
Route: SQ
t ½: 0.5 hours
Dosing: Infused over 8-12 hrs
5-7 nights/week
Deferasirox (Exjade®)
Route: PO
t ½: 12-16 hours
Dosing: Dissolved in solution, taken daily
Pharmacotherapy In MDS
Azacitidine
Decitabine
Lenalidomide
Anti-thymocyte Globulin (ATG)
IPSS
Median Survival in MDS
Large pronormoblast in pervovirus
infection.
Differential Diagnosis
Non-neoplastic simulators
Other myelodysplastic disorders
eoplastic disorders may simulate myelodysplasia
Vitamin/micronutrient deficiencies
B12/folate
Copper
Ring sideroblasts present
Cytoplasmic vacuoles
May be due to
Zinc excess
Gastrectomy
Total parenteral nutrition
Infections
HIV
Parvovirus
HHV-6 in children
Toxins
Ethanol
Heavy metals
Growth factors
-macrophage colony-stimulating factor (GMCSF
Erythropoietin
Drugs (numerous)

More Related Content

What's hot

Myeloproliferative disorder
Myeloproliferative disorderMyeloproliferative disorder
Myeloproliferative disorder
ariva zhagan
 
MDS/MPN (2021)
MDS/MPN (2021)MDS/MPN (2021)
MDS/MPN (2021)
Ahmed Makboul
 
Acute myeloid leukemia
Acute myeloid leukemiaAcute myeloid leukemia
Acute myeloid leukemia
Athira RG
 
Renal pediatric tumors
Renal pediatric tumorsRenal pediatric tumors
Renal pediatric tumors
MIMSR Medical college,Latur
 
Chronic myeloid Leukemia
Chronic myeloid LeukemiaChronic myeloid Leukemia
Chronic myeloid Leukemia
MLT LECTURES BY TANVEER TARA
 
Myelodysplastic syndrome by dr narmada
Myelodysplastic syndrome by dr narmadaMyelodysplastic syndrome by dr narmada
Myelodysplastic syndrome by dr narmada
Narmada Tiwari
 
Polycythemia vera jak2
Polycythemia vera jak2Polycythemia vera jak2
Polycythemia vera jak2
abhishek3096
 
Chronic leukemias
Chronic leukemiasChronic leukemias
Chronic leukemias
Vijay Shankar
 
Haematological Malignancies
Haematological MalignanciesHaematological Malignancies
Haematological Malignanciesmeducationdotnet
 
Acute leukemias aml-csbrp
Acute leukemias aml-csbrpAcute leukemias aml-csbrp
Acute leukemias aml-csbrp
Prasad CSBR
 
Minimal Residual Disease in Acute lymphoblastic leukemia
Minimal Residual Disease in Acute lymphoblastic leukemiaMinimal Residual Disease in Acute lymphoblastic leukemia
Minimal Residual Disease in Acute lymphoblastic leukemia
Dr. Liza Bulsara
 
Acute Myeloid Leukemia
Acute Myeloid Leukemia Acute Myeloid Leukemia
Acute Myeloid Leukemia
MLT LECTURES BY TANVEER TARA
 
Plasma cell dyscrasias
Plasma cell dyscrasias Plasma cell dyscrasias
Plasma cell dyscrasias
Prince Lokwani
 
leukemoid reaction and leukemia
leukemoid reaction and leukemialeukemoid reaction and leukemia
leukemoid reaction and leukemia
priya jaswani
 
Myelodysplastic syndrome
Myelodysplastic syndromeMyelodysplastic syndrome
Myelodysplastic syndrome
Dr. Pritika Nehra
 
Approach to undifferentiated tumors
Approach to undifferentiated tumorsApproach to undifferentiated tumors
Approach to undifferentiated tumors
Dr. Varughese George
 
sideroblastic anemia
sideroblastic anemiasideroblastic anemia
sideroblastic anemia
MLT LECTURES BY TANVEER TARA
 
Classification and diagnostic approach to fnac of mediastinal
Classification and diagnostic approach to fnac of mediastinalClassification and diagnostic approach to fnac of mediastinal
Classification and diagnostic approach to fnac of mediastinal
Indira Shastry
 
Myeloproliferative disorders
Myeloproliferative disordersMyeloproliferative disorders
Myeloproliferative disorders
drsapnaharsha
 
Myelodysplastic syndrome
Myelodysplastic syndromeMyelodysplastic syndrome
Myelodysplastic syndrome
ajayyadav753
 

What's hot (20)

Myeloproliferative disorder
Myeloproliferative disorderMyeloproliferative disorder
Myeloproliferative disorder
 
MDS/MPN (2021)
MDS/MPN (2021)MDS/MPN (2021)
MDS/MPN (2021)
 
Acute myeloid leukemia
Acute myeloid leukemiaAcute myeloid leukemia
Acute myeloid leukemia
 
Renal pediatric tumors
Renal pediatric tumorsRenal pediatric tumors
Renal pediatric tumors
 
Chronic myeloid Leukemia
Chronic myeloid LeukemiaChronic myeloid Leukemia
Chronic myeloid Leukemia
 
Myelodysplastic syndrome by dr narmada
Myelodysplastic syndrome by dr narmadaMyelodysplastic syndrome by dr narmada
Myelodysplastic syndrome by dr narmada
 
Polycythemia vera jak2
Polycythemia vera jak2Polycythemia vera jak2
Polycythemia vera jak2
 
Chronic leukemias
Chronic leukemiasChronic leukemias
Chronic leukemias
 
Haematological Malignancies
Haematological MalignanciesHaematological Malignancies
Haematological Malignancies
 
Acute leukemias aml-csbrp
Acute leukemias aml-csbrpAcute leukemias aml-csbrp
Acute leukemias aml-csbrp
 
Minimal Residual Disease in Acute lymphoblastic leukemia
Minimal Residual Disease in Acute lymphoblastic leukemiaMinimal Residual Disease in Acute lymphoblastic leukemia
Minimal Residual Disease in Acute lymphoblastic leukemia
 
Acute Myeloid Leukemia
Acute Myeloid Leukemia Acute Myeloid Leukemia
Acute Myeloid Leukemia
 
Plasma cell dyscrasias
Plasma cell dyscrasias Plasma cell dyscrasias
Plasma cell dyscrasias
 
leukemoid reaction and leukemia
leukemoid reaction and leukemialeukemoid reaction and leukemia
leukemoid reaction and leukemia
 
Myelodysplastic syndrome
Myelodysplastic syndromeMyelodysplastic syndrome
Myelodysplastic syndrome
 
Approach to undifferentiated tumors
Approach to undifferentiated tumorsApproach to undifferentiated tumors
Approach to undifferentiated tumors
 
sideroblastic anemia
sideroblastic anemiasideroblastic anemia
sideroblastic anemia
 
Classification and diagnostic approach to fnac of mediastinal
Classification and diagnostic approach to fnac of mediastinalClassification and diagnostic approach to fnac of mediastinal
Classification and diagnostic approach to fnac of mediastinal
 
Myeloproliferative disorders
Myeloproliferative disordersMyeloproliferative disorders
Myeloproliferative disorders
 
Myelodysplastic syndrome
Myelodysplastic syndromeMyelodysplastic syndrome
Myelodysplastic syndrome
 

Similar to Mds

Myelodysplastic Syndrome
Myelodysplastic SyndromeMyelodysplastic Syndrome
Myelodysplastic SyndromeDr. Nurul Azam
 
myelodysplastic syndrome
myelodysplastic syndromemyelodysplastic syndrome
myelodysplastic syndrome
arvindra rahul
 
MYELODYSPLASTICSYNDROMES.ppt
MYELODYSPLASTICSYNDROMES.pptMYELODYSPLASTICSYNDROMES.ppt
MYELODYSPLASTICSYNDROMES.ppt
MarwaGamaleldin1
 
MYELODYSPLASTIC SYNDROME-3.pptx
MYELODYSPLASTIC SYNDROME-3.pptxMYELODYSPLASTIC SYNDROME-3.pptx
MYELODYSPLASTIC SYNDROME-3.pptx
MEDTECH LAB
 
Myelodysplastic syndromes
Myelodysplastic syndromesMyelodysplastic syndromes
Myelodysplastic syndromes
dr pushkar chaudhary
 
Myelodysplasticsyndromes
MyelodysplasticsyndromesMyelodysplasticsyndromes
Myelodysplasticsyndromes
Born To Win
 
Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)
Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)
Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)
College of Medicine, Sulaymaniyah
 
Myelodysplastic syndrome (MDS)
Myelodysplastic syndrome (MDS)Myelodysplastic syndrome (MDS)
Myelodysplastic syndrome (MDS)
Swati Wadhai
 
Mds&mds mpn
Mds&mds mpnMds&mds mpn
Mds&mds mpn
Azza Elkady
 
myelodysplastic_syndromes.ppt
myelodysplastic_syndromes.pptmyelodysplastic_syndromes.ppt
myelodysplastic_syndromes.ppt
AntnaSinek
 
MDS.pptx
MDS.pptxMDS.pptx
MDS.pptx
SunandiniDas1
 
Myelodesplastic syndrome by haider zaman
Myelodesplastic syndrome by haider zamanMyelodesplastic syndrome by haider zaman
Myelodesplastic syndrome by haider zaman
Haider zaman
 
Pre leukemia MDS
Pre leukemia MDSPre leukemia MDS
Pre leukemia MDS
Appy Akshay Agarwal
 
ACUTE MYELOID LEUKAEMIA.pptx
ACUTE MYELOID LEUKAEMIA.pptxACUTE MYELOID LEUKAEMIA.pptx
ACUTE MYELOID LEUKAEMIA.pptx
chetanpattar7
 
V_Hematology_Forum_Prof_Gujral
V_Hematology_Forum_Prof_GujralV_Hematology_Forum_Prof_Gujral
V_Hematology_Forum_Prof_Gujral
EAFO1
 
Mds 1
Mds 1Mds 1
Mds csbrp
Mds csbrpMds csbrp
Mds csbrp
Prasad CSBR
 
MDS 1.pptx
MDS 1.pptxMDS 1.pptx
MDS 1.pptx
priyankkumar59
 

Similar to Mds (20)

Myelodysplastic Syndrome
Myelodysplastic SyndromeMyelodysplastic Syndrome
Myelodysplastic Syndrome
 
myelodysplastic syndrome
myelodysplastic syndromemyelodysplastic syndrome
myelodysplastic syndrome
 
MYELODYSPLASTICSYNDROMES.ppt
MYELODYSPLASTICSYNDROMES.pptMYELODYSPLASTICSYNDROMES.ppt
MYELODYSPLASTICSYNDROMES.ppt
 
MYELODYSPLASTIC SYNDROME-3.pptx
MYELODYSPLASTIC SYNDROME-3.pptxMYELODYSPLASTIC SYNDROME-3.pptx
MYELODYSPLASTIC SYNDROME-3.pptx
 
Myelodysplastic syndromes
Myelodysplastic syndromesMyelodysplastic syndromes
Myelodysplastic syndromes
 
Myelodysplasticsyndromes
MyelodysplasticsyndromesMyelodysplasticsyndromes
Myelodysplasticsyndromes
 
Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)
Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)
Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)
 
Myelodysplastic syndrome (MDS)
Myelodysplastic syndrome (MDS)Myelodysplastic syndrome (MDS)
Myelodysplastic syndrome (MDS)
 
Mds&mds mpn
Mds&mds mpnMds&mds mpn
Mds&mds mpn
 
myelodysplastic_syndromes.ppt
myelodysplastic_syndromes.pptmyelodysplastic_syndromes.ppt
myelodysplastic_syndromes.ppt
 
MDS.pptx
MDS.pptxMDS.pptx
MDS.pptx
 
Myelodesplastic syndrome by haider zaman
Myelodesplastic syndrome by haider zamanMyelodesplastic syndrome by haider zaman
Myelodesplastic syndrome by haider zaman
 
Pre leukemia MDS
Pre leukemia MDSPre leukemia MDS
Pre leukemia MDS
 
Mielodisplasia
MielodisplasiaMielodisplasia
Mielodisplasia
 
ACUTE MYELOID LEUKAEMIA.pptx
ACUTE MYELOID LEUKAEMIA.pptxACUTE MYELOID LEUKAEMIA.pptx
ACUTE MYELOID LEUKAEMIA.pptx
 
V_Hematology_Forum_Prof_Gujral
V_Hematology_Forum_Prof_GujralV_Hematology_Forum_Prof_Gujral
V_Hematology_Forum_Prof_Gujral
 
Mds 1
Mds 1Mds 1
Mds 1
 
Mds 1
Mds 1Mds 1
Mds 1
 
Mds csbrp
Mds csbrpMds csbrp
Mds csbrp
 
MDS 1.pptx
MDS 1.pptxMDS 1.pptx
MDS 1.pptx
 

More from ariva zhagan

Complement system
Complement systemComplement system
Complement system
ariva zhagan
 
Phagocytosis
PhagocytosisPhagocytosis
Phagocytosis
ariva zhagan
 
Free radical injury
Free radical injuryFree radical injury
Free radical injury
ariva zhagan
 
Cell injury
Cell injuryCell injury
Cell injury
ariva zhagan
 
Cellular unit in health disease
Cellular unit in health diseaseCellular unit in health disease
Cellular unit in health disease
ariva zhagan
 
Special stains in dermato pathology - final copy
Special stains in dermato pathology - final copySpecial stains in dermato pathology - final copy
Special stains in dermato pathology - final copy
ariva zhagan
 
Role of ihc on soft tissue tumours
Role of ihc on soft tissue tumoursRole of ihc on soft tissue tumours
Role of ihc on soft tissue tumours
ariva zhagan
 
Renal failure
Renal failureRenal failure
Renal failure
ariva zhagan
 
Refreactory anemia
Refreactory anemiaRefreactory anemia
Refreactory anemia
ariva zhagan
 
Processing of tissue
Processing of tissueProcessing of tissue
Processing of tissue
ariva zhagan
 
Poorly differentiated neoplasms
Poorly differentiated neoplasmsPoorly differentiated neoplasms
Poorly differentiated neoplasms
ariva zhagan
 
Polycythemia
PolycythemiaPolycythemia
Polycythemia
ariva zhagan
 
Peadiatric infections
Peadiatric infectionsPeadiatric infections
Peadiatric infections
ariva zhagan
 
Pathology definitions
Pathology definitionsPathology definitions
Pathology definitions
ariva zhagan
 
Paroxysmal nocternal hemoglobinuria
Paroxysmal nocternal hemoglobinuriaParoxysmal nocternal hemoglobinuria
Paroxysmal nocternal hemoglobinuria
ariva zhagan
 
Paraneoplastic syndrome
Paraneoplastic syndromeParaneoplastic syndrome
Paraneoplastic syndrome
ariva zhagan
 
Ovarian neoplasms
Ovarian neoplasmsOvarian neoplasms
Ovarian neoplasms
ariva zhagan
 
Nutritional disease
Nutritional diseaseNutritional disease
Nutritional disease
ariva zhagan
 
Myeloproliferative disorder
Myeloproliferative disorderMyeloproliferative disorder
Myeloproliferative disorder
ariva zhagan
 

More from ariva zhagan (20)

Complement system
Complement systemComplement system
Complement system
 
Phagocytosis
PhagocytosisPhagocytosis
Phagocytosis
 
Free radical injury
Free radical injuryFree radical injury
Free radical injury
 
Cell injury
Cell injuryCell injury
Cell injury
 
Cellular unit in health disease
Cellular unit in health diseaseCellular unit in health disease
Cellular unit in health disease
 
Special stains in dermato pathology - final copy
Special stains in dermato pathology - final copySpecial stains in dermato pathology - final copy
Special stains in dermato pathology - final copy
 
Role of ihc on soft tissue tumours
Role of ihc on soft tissue tumoursRole of ihc on soft tissue tumours
Role of ihc on soft tissue tumours
 
Renal failure
Renal failureRenal failure
Renal failure
 
Refreactory anemia
Refreactory anemiaRefreactory anemia
Refreactory anemia
 
Processing of tissue
Processing of tissueProcessing of tissue
Processing of tissue
 
Poorly differentiated neoplasms
Poorly differentiated neoplasmsPoorly differentiated neoplasms
Poorly differentiated neoplasms
 
Polycythemia
PolycythemiaPolycythemia
Polycythemia
 
Pem
PemPem
Pem
 
Peadiatric infections
Peadiatric infectionsPeadiatric infections
Peadiatric infections
 
Pathology definitions
Pathology definitionsPathology definitions
Pathology definitions
 
Paroxysmal nocternal hemoglobinuria
Paroxysmal nocternal hemoglobinuriaParoxysmal nocternal hemoglobinuria
Paroxysmal nocternal hemoglobinuria
 
Paraneoplastic syndrome
Paraneoplastic syndromeParaneoplastic syndrome
Paraneoplastic syndrome
 
Ovarian neoplasms
Ovarian neoplasmsOvarian neoplasms
Ovarian neoplasms
 
Nutritional disease
Nutritional diseaseNutritional disease
Nutritional disease
 
Myeloproliferative disorder
Myeloproliferative disorderMyeloproliferative disorder
Myeloproliferative disorder
 

Recently uploaded

Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Sandy Millin
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
beazzy04
 
How to Split Bills in the Odoo 17 POS Module
How to Split Bills in the Odoo 17 POS ModuleHow to Split Bills in the Odoo 17 POS Module
How to Split Bills in the Odoo 17 POS Module
Celine George
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
Home assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdfHome assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdf
Tamralipta Mahavidyalaya
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
Jisc
 
Fish and Chips - have they had their chips
Fish and Chips - have they had their chipsFish and Chips - have they had their chips
Fish and Chips - have they had their chips
GeoBlogs
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
siemaillard
 
Cambridge International AS A Level Biology Coursebook - EBook (MaryFosbery J...
Cambridge International AS  A Level Biology Coursebook - EBook (MaryFosbery J...Cambridge International AS  A Level Biology Coursebook - EBook (MaryFosbery J...
Cambridge International AS A Level Biology Coursebook - EBook (MaryFosbery J...
AzmatAli747758
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
Pavel ( NSTU)
 
Basic phrases for greeting and assisting costumers
Basic phrases for greeting and assisting costumersBasic phrases for greeting and assisting costumers
Basic phrases for greeting and assisting costumers
PedroFerreira53928
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
RaedMohamed3
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
Vikramjit Singh
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
Balvir Singh
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
TechSoup
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
Jisc
 
The Art Pastor's Guide to Sabbath | Steve Thomason
The Art Pastor's Guide to Sabbath | Steve ThomasonThe Art Pastor's Guide to Sabbath | Steve Thomason
The Art Pastor's Guide to Sabbath | Steve Thomason
Steve Thomason
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
Jisc
 

Recently uploaded (20)

Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
 
How to Split Bills in the Odoo 17 POS Module
How to Split Bills in the Odoo 17 POS ModuleHow to Split Bills in the Odoo 17 POS Module
How to Split Bills in the Odoo 17 POS Module
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
Home assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdfHome assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdf
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
 
Fish and Chips - have they had their chips
Fish and Chips - have they had their chipsFish and Chips - have they had their chips
Fish and Chips - have they had their chips
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
 
Cambridge International AS A Level Biology Coursebook - EBook (MaryFosbery J...
Cambridge International AS  A Level Biology Coursebook - EBook (MaryFosbery J...Cambridge International AS  A Level Biology Coursebook - EBook (MaryFosbery J...
Cambridge International AS A Level Biology Coursebook - EBook (MaryFosbery J...
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
 
Basic phrases for greeting and assisting costumers
Basic phrases for greeting and assisting costumersBasic phrases for greeting and assisting costumers
Basic phrases for greeting and assisting costumers
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
 
The Art Pastor's Guide to Sabbath | Steve Thomason
The Art Pastor's Guide to Sabbath | Steve ThomasonThe Art Pastor's Guide to Sabbath | Steve Thomason
The Art Pastor's Guide to Sabbath | Steve Thomason
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
 

Mds

  • 1. MODERATOR – Prof. DR. - ANIL KAPOORMODERATOR – Prof. DR. - ANIL KAPOOR
  • 2. What Is Myelodysplastic Syndrome? The myelodysplastic syndromes are a group of disorders characterized by one or more peripheral blood cytopenias secondary to bone marrow dysfunction.  In MDS the bone marrow cannot produce blood cells effectively, and many of the blood cells formed are defective. These abnormal blood cells are usually destroyed before they leave the bone marrow or shortly after entering the bloodstream. As a result, patients have shortages of blood cells, which are reflected in their low blood
  • 3. Characteristics Varying degree of tri-lineage cytopenia ( red blood cells, white blood cells and platelets). Dysplasia Normocellular or hypercellular B.M. May progress to acute leukaemia
  • 4. Incidence 1- Disease of elderly. 2- Median age is 65 years. 3- <10% are younger than 50 years. 4- Incidence rates 1/100,000 pop./ years. 5- Incidence rise to 1/1000 / years in > 60 years old. 6- Male slightly higher than female
  • 5. MDS Etiology Two etiologic categories of MDS: 1.) De Novo: Associated with: -benzene exposure (gasoline) -cigarette smoking -viruses -Fanconi’s anemia 2.) Therapy related: Associated with: -alkylating agent chemotherapy -radiation
  • 6. Aetiological Agents  Tobacco smoke.  Ionizing radiation.  Organic chemicals (such as benzene, toluene, xylene, and chloramphenicol).  Heavy metals.  Herbicides.  Pesticides.  Fertilizers.  Stone and cereal dusts.  Exhaust gases.  Nitro-organic explosives.  Petroleum and diesel derivatives.  Alkylating agents.  Marrow-damaging agents used in cancer chemotherapy.
  • 7. Pathophysiology: Contributing Factors MDS Stem cell dysfunction Stem Cell Dysfunction ApoptosisApoptosis Stromal/ angiogenic factors Stromal/ angiogenic factors Epigenetic changes Epigenetic changes Immune dysfunction Immune dysfunction Environmental direct toxicity Environmental direct toxicity Mutations/ DNA damage Mutations/ DNA damage With Permission of J. Maciejewski, M.D. Taussig Cancer Center/ Cleveland Clinic Foundation
  • 9. Dyserythropoiesis Anemia Normocytic or macro-ovalocytes Low retic count NRBC Megaloblastic changes Ringed sideroblast Pappenheimer bodies Basophilic stippling
  • 10.
  • 11.
  • 12.
  • 15.
  • 16.
  • 17. Blasts in MDS Type I blasts No granules Prominent nucleoli Central nucleus Type II and III blasts Few 1o granules Prominent nucleoli Central nucleus Promyelocyte Many 1o granules Less prominent nucleoli Eccentric nucleus
  • 18. Type I Blast Type III Blast
  • 19. Dysmegakaryopoiesis Low platelet count Giant Platelet Dwarf (micro) megakaryocyte
  • 21. Chromosomal abnormalities and MDS Chromosomal abnormalities are present in up to 50%of de novo cases of MDS and in virtually all cases of secondary MDS. The most common are:  Abnormality - 7 +7 +8 5q- 7q- 11q- 12q- 13q- 20q- inv3 i(17q) t(1;3) t(1;7) t(3;3)  Frequency(%) 15 5 19 27 4 7 5 2 5 1 5 1 2 1
  • 22. Deletion of the long arm of chromosome 5 (5q- syndrome ) Strongly associated with RA. 5q- accounts for up to 70% of cytogenetic abnormalities in this subtype. The q arm of chromosome 5 is particularly rich in genes, which encoded haemopoietic growth factors and their receptors. For example , IL-3 , IL-4 , IL-5 , GM-CSF and the M-CSF receptor are located in this region. The potential for the loss of any or all of these genes contribute to the disruption of ordered haemopoiesis.
  • 23. Monosmy 7 and 7q- Most strongly associated with secondary MDS. Associated with the loss of a major surface glycoprotein (gp 130) in neutrophile and susceptibility to bacterial infection secondary to impaired granulocyte monocyte chemotatic activity.
  • 24. Deletion of the q arm of chromosome 11 (11q-) Account for 20% of the chromosomal abnormalities in RAS. This abnormality is associated with raised iron stores and high ring sidroblast counts.  The presence of the gene , which encoded the H- subunit of ferritin at chromosome 11 , may explain this
  • 25. Abnormalities of chromosome 17 (i17q) It involves the loss or disruption of the Р53 tumor suppressor gene are seen in CML in association with transformation to the blastic phase and in up to 5% of cases of primary MDS.  This predisposes to certain dysplastic features and neutrophil vaculation.
  • 26. Abnormalities of chromosome 3 Dysmegakaryopiesis and thombocytosis appear to be associated with Abnormalities of chromosome 3
  • 27. The importance of indication of chromosomal abnormalities To confirm diagnoses .  To know the stage of disease. To know the direction of progression of disease. Multiple genetic abnormalities indicate late events in MDS.
  • 28. Abnormal localization of immature precursors Presence of 3 or more small clusters of myeloblasts and promyelocytes (5 – 8 cells) in marrow trephine biopsy in the central portion of the marrow away from the vascular structure and the endosteal surface of the bone trabeculae
  • 29. Abnormal localization of immature precursors
  • 30. Signs and Symptoms Excessive tiredness, shortness of breath, and pale skin can be caused by anemia (shortage of red blood cells). Serious infections with high fevers can be caused by leukopenia (not having enough normal white blood cells) and, in particular, by having neutropenia or granulocytopenia (too few mature granulocytes). Excessive bruising and bleeding, for example, frequent or severe nosebleeds and/or bleeding from the gums, can be due to thrombocytopenia (not having enough of the blood platelets needed for plugging holes in damaged blood vessels).
  • 31. Physical Exam Hepatomegaly, splenomegaly, LAD: uncommon Except CMML Cutaneous manifestations: uncommon Sweet’s syndrome( neutrophilic dermatosis): transformation to acute leukemia ( IL-6) Granulocytic sarcoma (chloroma): herald disease transformation into acute leukemia
  • 33. FAB classification scheme in 1985 for MDS
  • 34. Refractory Anemia RA Definition: Dyplasia of the erythroid series only. Clinically, anemia is refractory to hematinic therapy Myeloblasts < 1% blood and < 5% marrow <15% ringed sideroblasts in marrow No Auer rods Other etiologies of erythroid abnormalities must be excluded. These include: drug/toxin exposure -vitamin deficiency viral infection -congenital disease
  • 35. Refractory Anemia Epidemiology: 5-10% of MDS cases. Older patients Morphology: Anisopoikilocytosis on peripheral smears Dyserythropoiesis with nuclear abnormalities (megaloblastoid change) < 15% ringed sideroblasts
  • 36. Refractory Anemia Genetics: 25% may have genetic abnormalities Prognosis: Median survival is 66 months 6% rate of progression to acute leukemia
  • 37. Peripheral Smear - Anisopoikilocytosis
  • 38. Megaloblastoid Change on Bone Marrow Aspirate
  • 39. Refractory Anemia with Ringed Sideroblasts RARS definition: Dyplasia of the erythroid series only. Clinically, anemia is refractory to hematinic therapy Myeloblasts < 5% in marrow, absent in blood >15% ringed sideroblasts in marrow No Auer rods Other etiologies of ringed sideroblasts must be excluded. These include: Anti- tuberculosis drugs Alcoholism
  • 40. Refractory Anemia with Ringed Sideroblasts Epidemiology: 10-12% of MDS cases. Older patients Males > females Morphology: Dimorphic pattern on peripheral smears Majority RBC’s normochromic, 2nd population hypochromic Dyserythropoiesis with nuclear abnormalities (megaloblastoid change)
  • 41. Refractory Anemia with Ringed Sideroblasts Genetics: Clonal chromosomal abnormalities in  <10%; in fact, development of such an abnormality should prompt reassessment of diagnosis. Prognosis: Median survival 6 years (72 months) 1-2% rate of progression to acute leukemia
  • 42. Dimorphic Red Cell Population
  • 46. Refractory Anemia with Excess Blasts RAEB definition: Refractory anemia with 5-19% myeloblasts in the bone marrow. RAEB-1:  5-9% blasts in bone marrow and <5% blasts in blood. RAEB-2:  10-19% blasts in the bone marrow  Auer rods present
  • 47. Refractory Anemia with Excess Blasts Epidemiology: 40% of MDS cases. Older patients (over 50 years) Morphology: Dysplasia of all three cell lines often present Neutrophil abnormalities may include: Hypogranulation Pseudo-Pelger-huet (hyposegmentation/barbells) Megkaryocyte abnormalities may include Hypolobation -Micromegakaryocytes
  • 48. Refractory Anemia with Excess Blasts Morphology (con’t.) Erythroid precursor abnormalities may include: Abnormal lobulation -megaloblastoid change Multinucleation 0-19% myeloblasts in the blood 5-19% in the marrow Bone marrow: Usually hypercellular (10-15% hypocellular) Abnormal localization of immature precursors (ALIP) may be present Immunophenotype: Blasts express CD 13, CD33 or CD117
  • 49. Refractory Anemia with Excess Blasts Genetics: Clonal chromosomal abnormalities found in 30% - 50% of RAEB cases. The abnormalities include: +8 – -5 – del(5q) – -7 – del(7q) – Complex karyotypes Prognosis: Median survival, RAEB-1 = 18 months Median survival, RAEB-2 = 10 months RAEB-1 = 25% rate of progression to acute leukemia RAEB-2 = 33% rate of progression to acute leukemia
  • 52. Refractory Anemia with Excess Blasts in Transformation (RAEB-t) • 21-30 percent blasts in the marrow; more than 5 percent in the bloodstream • normal or hypercellular (filled with cells) marrow • accounts for about 25 percent of cases
  • 53. Chronic Myelomonocytic Leukemia (CMML) • 5-20 percent blasts in the marrow; less than 5 percent in the bloodstream • cytopenia of at least two cell lines • normal or hypercellular (filled with cells) marrow • accounts for 15 to 20 percent of cases.
  • 54. CMML  Splenomegaly (10%)  Maculopapular skin infiltration  Monocytic pleural or pericardial effusion  JMML (MPD/MDS) 1. Pallor, bleeding, hepatosplenomegaly, skin involvement
  • 55. WHO Refractory anemia Refractory anemia e ringed siderblast Refractory cytopenia e multilineage dysplasia Refractory cytopenia e multilineage dysplasia & ringed sideroblasts Refractory anemia e excess blast-1 Refractory anemia e excess blast-2 Myelodysplastic syndrome unclassified MDS associated e isolated del (5q)
  • 56. WHO Subtype Blood Bone Marrow RA Anemia Erythroid dysplasia only RARS Anemia Erythroid dys >15% ringed RCMD Bi- pancytopenia >10%Dysp in 2 or more cell lineage RCMD-RS Bi-pancytopenia >10%Dys 2 or more cell lineage >15% ringed
  • 57. WHO subtype Blood Bone Marrow RAEB-1 Cytopenia <5% blast Uni-multilineage dys, 5-9%blast RAEB-2 Cytopenia, 5-19%blast or Auer rods Uni-multi dys 10-19%blast Or Auer rods MDS-U cytopenia Myeloid or megakaryocte dys MDS with 5q Anemia,nor or increased PLT Mega e hypolobated nuclei, <5%blast
  • 58. Prognostic Groups Two groups based on survival and evolution to acute leukemia 1.) “Good” group Refractory anemia (RA) Refractory anemia with ringed sideroblasts (RARS) 5q - syndrome 2.) “Bad” group Refractory anemia with excess blasts (RAEB) Refractory anemia with excess blasts in transformation (RAEB-t) CMML MDS unclassified can be either
  • 59. International Prognostic Scoring System (IPSS) Factors (1) the percentage of blasts in the bone marrow. (2)whether chromosome abnormalities are present and, if so, which ones. (3)how low the patient's blood counts are. These are given a score; the lowest scores have the best outlook for survival.
  • 60. Prognostic Scoring The International Myelodysplastic Syndrome Working Group developed a scoring system based on 3 variables: 00 0.50.5 1.01.0 1.51.5 2.02.0 % Blasts% Blasts <5<5 5-105-10 ---- 11-2011-20 20-3020-30 KaryotypKaryotyp ee Normal, -Y,Normal, -Y, del(5q),del(5q), del(20q)del(20q) SingleSingle karyotypickaryotypic anomaly,anomaly, DoubleDouble abnormaliyabnormaliy ≥≥ 33 abnormalities,abnormalities, chr 7chr 7 abnormalitiesabnormalities Chr 3 abn.Chr 3 abn. CytopeniCytopeni aa 0-10-1 2-32-3
  • 62. MDS: Differential Diagnosis B12/folate deficiency Heavy metals (Arsenic) Congenital dyserythropoietic anemia Parvovirus B19 GCSF therapy (increased blasts)
  • 63. Treatment o Chemotherapy. o Supportive therapy, such as WBCs, RBCs, Platelets transfusions. o B.M transplantation in young patients.
  • 64.
  • 65. THANK YOU SPEAKER- DR. Narmada Prasad TiwariSPEAKER- DR. Narmada Prasad Tiwari
  • 66. Prevention & Treatment of Infections Prevention Prophylactic antibiotics  no role Patient education  know your nadir report a fever recognize signs of infection avoid illness, crowds update vaccinations Treatment  Febrile neutropenia guidelines www.nccn.org/MDS v1..2008
  • 67. Iron Chelation Options Deferoxamine (Desferal®) Route: SQ t ½: 0.5 hours Dosing: Infused over 8-12 hrs 5-7 nights/week Deferasirox (Exjade®) Route: PO t ½: 12-16 hours Dosing: Dissolved in solution, taken daily
  • 69. IPSS
  • 71. Large pronormoblast in pervovirus infection.
  • 72. Differential Diagnosis Non-neoplastic simulators Other myelodysplastic disorders eoplastic disorders may simulate myelodysplasia Vitamin/micronutrient deficiencies B12/folate Copper Ring sideroblasts present Cytoplasmic vacuoles May be due to Zinc excess Gastrectomy Total parenteral nutrition Infections HIV Parvovirus HHV-6 in children Toxins Ethanol Heavy metals Growth factors -macrophage colony-stimulating factor (GMCSF Erythropoietin Drugs (numerous)